Skip to main content
Hauptrubriken
Zeitschriften Fortbildung Hebammen Bücher Kongresse & Live-Webinare
Social Media - Folgen Sie uns!
Instagram Facebook LinkedIn Instagram Hebammen
Service
Jobbörse Kundenservice Info & Hilfe
Fokus-Themen
Chronisch-entzündliche Darmerkrankung COVID-19-Update Diabetes Hautpflege Klima & Gesundheit Hygiene Intensivpflege Kardiologische Pflege Mobilisation Nachhaltigkeit Nierenerkrankungen Obstipation Onkologische Pflege Palliativpflege Schmerz Sucht in der Pflege Vielfalt, Gleichberechtigung und Inklusion Wundversorgung
Erweiterte Suche
Anmelden
nach oben
Notfall + Rettungsmedizin
Erschienen in:

12.04.2017 | CME

Nicht-Vitamin-K-abhängige orale Antikoagulanzien

Notfallmanagement bei Patienten mit Blutungen unter oraler Antikoagulation

verfasst von: Priv.-Doz. Dr. med. J. Koscielny, Dr. C. Rosenthal, Prof. Dr. C. von Heymann

Erschienen in: Notfall + Rettungsmedizin | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Trotz des breiten Einsatzes nicht-Vitamin-K-abhängiger oraler Antikoagulanzien (NOAK) sowie Empfehlungen von Zulassungsbehörden und interdisziplinären Expertengremien zum Umgang in der Blutungssituation unter NOAK-Antikoagulation besteht insbesondere in Krankenhäusern ohne hämostaseologischen Schwerpunkt große Handlungsunsicherheit. Bei aus klinischer Sicht leichten Blutungen sind die medizinische Überwachung dieser Patienten und die Verzögerung der nächsten Einnahme oder das passagere Absetzen anzuraten. Bei mittelschweren bis schweren Blutungen richten sich die primären Maßnahmen auf die Stabilisierung der Herz-Kreislauf-Funktion und parallel auf die Behandlung, je nach Lokalisation des Blutungsherdes. Vital bedrohliche, z. B. intrakranielle Blutungen erfordern neben den Maßnahmen der hämodynamischen Stabilisierung ein spezielles Hämostasemanagement, das vorwiegend klinisch orientiert sein sollte.
Vorheriger Artikel Rechtliche Rahmenbedingungen in der präklinischen Notfallversorgung
Nächster Artikel Retraction Note zu: Therapie mit Blutprodukten
Fußnoten
1
C „congestive heart failure“ (Herzinsuffizienz), H Hypertension, A 2 Alter ≥75 Jahre (doppelt), D Diabetes mellitus, S2 „stroke“ (Schlaganfall; doppelt), transitorische ischämische Attacke oder Thromboembolie, V vaskuläre Erkrankungen wie periphere arterielle Verschlusskrankheit oder Herzinfarkt, A Alter 65 bis 74 Jahre, Sc „sex category“ (weibliches Geschlecht).
 
Literatur
1.
Camm AJ, Lip GY, De Caterina R et al (2012) focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation-developed with special contribution of the European Heart Rhythm Association. Europace 14:1385–1413CrossRefPubMed
2.
Connolly SJ, Ezekowitz MD, Yussuf S, Reilley PA, Wallentin L (2010) Newly identified events in the RE-LY trial. N Engl J Med 363:1875–1876CrossRefPubMed
3.
Chai-Adisaksopha C, Crowther M, Isayama T, Lim W (2014) The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 124(15):2450–2458CrossRefPubMed
4.
Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W (2012) Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 126:2381–2391CrossRefPubMed
5.
Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W et al (2015) Updated European Heart Rhythm Association (EHRA) practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17:1467–1507CrossRefPubMed
6.
Kovacs RJ, Flaker G, Saxonhouse S, Doherty J, Birtcher K, Cuker A, Davidson B, Giugliano R, Granger C, Jaffer A, Metha B, Nutescu E, Williams K (2015) Practical management of anticoagulation in patients with atrial fibrillation. J Am Coll Cardiol 65(13):1340–1360CrossRefPubMed
7.
Cotton B, McCarthy J, Holcomb J (2011) Acutely injured patients on dabigatran. N Engl J Med 365(21):2039–2040CrossRefPubMed
8.
Gomez-Outes A, Terleira-Fernandez A, Lecumberri R, Suarez-Gea M, Vargas-Castrillon E (2014) Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thromb Res 134(4):774–782CrossRefPubMed
9.
Caldeira D, Rodrigues F, Barra M, Santos AT, De Abreu D, Goncalves N, Pinto F, Ferreira J, Costa J (2015) Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. Heart 101:1204–1211CrossRefPubMed
10.
Ruff C, Giugliano R, Braunwald E, Hoffmann E, Deenadayalu N, Ezekowitz M, Camm A, Weitz J, Lewis B, Parkhomenko A, Yamashita T, Antman E (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383(9921):955–962CrossRefPubMed
11.
Inui T, Parina R, Chang D, Inui T, Coimbra R (2014) Mortality after ground-level fall in the elderly patients taking oral anticoagulation for atrial fibrillation/flutter: A long-term analysis of risks versus benefit. J Trauma Acute Care Surg 76(3):642–649CrossRefPubMed
12.
Peck KA, Calvo R, Schlechter M, Sise C, Kahl J, Shackford M, Shackford S, Sise M, Blaskiewicz D (2014) The impact of preinjury anticoagulants and prescription antiplatelet agents on outcomes in older patients with traumatic brain injury. J Trauma Acute Care Surg 76(2):431–436CrossRefPubMed
13.
14.
Lödgers T, Lefering R, Schneppendahl J, Alldinger I, Witte I, Windolf J, Flohé S (2010) Abbruch der Schockraumdiagnostik und Notfalloperation beim Polytrauma: Inzidenz und klinische Relevanz. Unfallchirurg 10:832–838
15.
Wutzler S, Maegele M, Marzi I, Spanholtz T, Wafaisade A, Lefering R (2009) TR-DGU. Association of preexisting medical conditions with in-hospital mortality in multiple-trauma patients. J Am Coll Surg 209(1):75–81CrossRefPubMed
16.
Batchelor JS, Grayson A (2012) A meta-analysis to determine the effect of anticoagulation on mortality in patients with blunt head trauma. Br J Neurosurg 26(4):525–530CrossRefPubMed
17.
Stangier J, Rathgen K, Stahle H, Mazur D (2010) Influence of renal impairment on the pharmacokinetics and pharmakodynamics of oral dabigatran etexilate: An open-label, parallel-group, single-centre study. Clin Pharmacokinet 49:259–268CrossRefPubMed
18.
Van Ryn J, Stangier J, Haertter S et al (2010) Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103:1116–1127CrossRefPubMed
19.
Wang Y, Bajorek B (2014) New oral anticoagulants in practice: phamacological and practical considerations. Am J Cardiovasc Drugs 14(3):175–189CrossRefPubMed
20.
21.
22.
FDA Drug Safety Communication (2014) FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin. Update on the risk for serious bleeding events with the anticoagulant Pradaxa (dabigatran) that was issued on November 2, 2012. http://​www.​fda.​gov/​Drugs/​DrugSafety/​ucm326580.​htm (Erstellt: 13. Mai 2014)
23.
Efird LM, Mishkin DS, Berlowitz DR, Ash AS, Hylek EM, Ozonoff A, Reisman JI, Zhao S, Jasuja GK, Rose AJ (2014) Stratifying the risks of oral anticoagulation in patients with liver disease. Circ Cardiovasc Qual Outcomes 7(3):461–467CrossRefPubMed
24.
Khadzhynov D, Wagner F, Formella S, Wiegert E, Moschetti V, Slowinski T et al (2013) Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost 109:596–605CrossRefPubMed
25.
Chai-Adisaksopha C, Hillis C, Lim W, Boonyawat K, Moffat K, Crowther M (2015) Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. J Thromb Haemost 13(10):1790–1798CrossRefPubMed
26.
Reilly P, Lehr T, Haertter S, Connolly S, Yusuf S, Eikelboom J, Ezekowitz M, Nehmiz G, Wang S, Wallentin L, RE-LY Investigators (2014) The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in artrial fibrillation patients: the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 63(4):321–328CrossRefPubMed
27.
Sibbing D, Spannagl M (2014) Direct oral anticoagulants and antiplatelet agents. Hamostaseologie 34(1):78–84CrossRefPubMed
28.
Cuker A, Siegal DM, Crowther MA, Garcia DA (2014) Laboratory measurements of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 64(11):1128–1139CrossRefPubMedPubMedCentral
29.
Baglin T (2013) The role of the laboratory in treatment with new oral anticoagulants. J Thromb Haemost 11(Suppl 1):122–128CrossRefPubMed
30.
Harenberg J, Krämer S, Du S, Weiss C, Krämer R (2013) Concept of a point of care test to detect new oral anticoagulants in urine samples. Thromb J 11(1):15CrossRefPubMedPubMedCentral
31.
Dias JD, Norem K, Doorneweerd D, Thurer RL, Popovsky M, Olmert L (2015) Use of thromboelastography (TEG) for the detection of new oral anticoagulants. Arch Pathol Lab Med 139(5):665–673CrossRefPubMed
32.
Dinkelaar J, Patiwael S, Harenberg J, Leyte A, Brinkmann HJ (2014) Global coagulation tests: Their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate. Clin Chem Lab Med 52(11):1615–1623PubMed
33.
Van Ryn J, Strangier J, Haertter S et al (2010) Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103:1116–1127CrossRefPubMed
34.
Spannagl M, Bauersachs R, Debus ES, Gawaz M, Gerlach H, Haas S, Hach-Wunderle V, Lindhoff-Last E, Riess H, Schellong S, Schinzel H, Bode C (2012) Dabigatran therapy – perioperative management and interpretation of coagulation tests. Hamostaseologie 32(4):294–305CrossRefPubMed
35.
Koscielny J, Rutkauskaite E (2015) Blutungen unter NOAK: Evidenz und praktisches Vorgehen (Bleedings under NOAC (non Vitamin-K dependent oral anticoagulants): Evidence and practical management). Hamostaseologie 35(Suppl 1):S43–S53PubMed
36.
Maegele M, Grottke O, Schöchl H, Sakowitz OA, Spannagl M, Koscielny J (2016) Direct oral anticoagulants in emergency trauma admissions. Dtsch Arztebl Int 113(35–36):575–582PubMed
37.
Faraoni D, Levy J, Albaladejo P, Samama C (2015) Groupe d’Interet en hemostase perioperative. Updates in the perioperative and emergency management of non-vitamin K antagonist oral antocoagulants. Crit Care 19(1):203CrossRefPubMedPubMedCentral
38.
Giebl A, Gürtler KK (2014) Neue orale Antikoagulanzien in der perioperativen Medizin. Anaesthesist 63:347–364CrossRefPubMed
39.
Koscielny J, Beyer-Westendorf J, von Heymann C et al (2012) Risk of bleeding and haemorrhagic complication with rivaroxaban – periprocedural management of haemostasis. Hamostaseologie 32:287–293CrossRefPubMed
40.
Pollack C, Reilley P, Eikelboom J et al (2015) Idarucizumab for dabigatran reversal. N Engl J Med 373:511–520CrossRefPubMed
41.
Spannagl M, Koscielny J, Kiesewetter H (2009) Aktuelle Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten der Bundesärztekammer, Kapitel 7: Prokoagulatoren, 4. Aufl., S 153–154
42.
Guyatt GH, Akl EA, Crowther M, Gutterman DD, American College of Chest (2012) Executive summary : antithrombotic therapy and prevention of thrombosis. Chest 141:7–47CrossRef
43.
Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G (2012) Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 108(2):8–12CrossRef
44.
Kaatz S, Crowther M (2013) Reversal of target-specific oral anticoagulants. J Thromb Thrombolysis 36:195–202CrossRefPubMed
45.
Dager W, Roberts A (2013) Reversing dabigatran in a life-threatening bleed occurring during cardiac ablation with factor eight inhibitor bypassing activity. Crit Care Med 41:42–46CrossRef
46.
Dager W, Roberts A (2011) Reversing dabigatran with Feiba in a patient with a transseptal perforation during cardiac ablation. Crit Care Med 39(Suppl 12):243–244
47.
Elg M, Carlsson S, Gustafsson S (2001) Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thromb Res 101:145–157CrossRefPubMed
48.
Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW (2012) Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 119(9):2172–2174CrossRefPubMed
49.
50.
Diaz MQ, Borobia AM, Nunez MA, Virto AM, Fabra S, Casado MS, Garcia-Erce JA, Samama CM (2013) Use of prothrombin complex concentrates for urgent reversal of dabigatran in the emergency depertment. Haematologica 98(11):e143–e144CrossRefPubMedPubMedCentral
51.
Majeed A, Schulman S (2013) Bleeding and antidotes in new oral anticoagulants. Best Pract Res Clin Haematol 26(2):191–202CrossRefPubMed
52.
Siegal DM, Garcia DA, Crowther MA (2014) How I treat target-specific oral anticoagulant-associatd bleeding. Blood 123(8):1152–1158CrossRefPubMed
53.
Levi M, Erenberg E, Kamphuisen PW (2011) Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost 9:1705–1712CrossRefPubMed
54.
Grottke O, van Ryn J, Spronk H, Rossaint R (2014) Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model. Crit Care 18:R27CrossRefPubMedPubMedCentral
55.
Honickel M, Treutler S, van Ryn J, Tillmann S, Rossaint R, Grottke O (2015) Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idaricizumab. Thromb Haemost 113:728–740CrossRefPubMed
56.
Honickel M, Maron B, van Ryn J, Braunschweig T, ten Cate H, Spronk H, Roissaint R, Grottke O (2016) Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model. Thromb Haemost 115(2):271–284CrossRefPubMed
57.
Honickel M, Braunschweig T, van Ryn J, ten Cate H, Spronk H, Rossaint R, Grottke O (2015) Prothrombin complex concentrate is effective in treating the antocoagulant affects of dabigatran in a porcine polytrauma model. Anaesthesiology 123(6):1350–1361CrossRef
58.
Beyer-Westendorf J, Förster K, Pannach S, Ebertz F, Gelbricht V, Thieme C, Michalski F, Köhler C, Werth S, Sahin K, Tittl L, Hänsel U, Weiss N (2014) Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAK registry. Blood 124(6):955–962CrossRefPubMedPubMedCentral
59.
Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E, Roquer J, Reverter JC, Sanz VV et al (2013) Reversal of apixaban induced alterations in haemostasis by different coagulation factor concentrates: Significance of studies in vitro with circulationg human blood. PLOS ONE 8:e78696CrossRefPubMedPubMedCentral
60.
Siegal D, Curnutte J, Connolly S, Lu G, Conoley P, Wiens B, Mathur V, Castillo J, Bronson M, Leeds J, Mar F, Gold A, Crowther M (2015) Andexanet alpha for the reversal of factor Xa inhibitor activity. N Engl J Med 373(25):2413–2424CrossRefPubMed
61.
Crowther M, Crowther MA (2015) Antidotes for novel oral anticoagulants: current status and future potential. Arterioscler Thromb Vasc Biol 35(8):1736–1745CrossRefPubMed
62.
Liotta EM, Levasseur-Franklin KE, Naidech AM (2015) Reversal of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban. Curr Opin Crit Care 21(2):127–133CrossRefPubMed
63.
Husted S, Verheugt FW, Comuth WJ (2016) Reversal strategies for NOACs: State of development, possible clinical applications and future persepectives. Drug Saf 39(1):5–13CrossRefPubMed
64.
Gomez-Outes A, Suarez-Gea M, Lecumberri R, Terleira-fernandez A, Vargas-Castrillon E (2014) Specific antidotes in development for reversal of novel anticoagulants. Recent Pat Cardiovasc Drug Discov 9(1):2–10CrossRefPubMed
65.
Connolly S et al (2016) Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 375:1131–1141CrossRefPubMed
66.
Getta B, Muller N, Motum P, Hsu D, Zebeljan D, Rosenfeld D (2015) Intermittend haemodialysis and continous veno-venous dialysis are effective in mitigating major bleeding due to dabigatran. Br J Haematol 169:603–604CrossRefPubMed
67.
Wang X, Mondal S, Wang J, Tirucherai G, Zhang D, Boyd RA, Frost C (2014) Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs 14(2):147–154CrossRefPubMed
68.
Hart RG, Diener HC, Yang S et al (2012) Intraccranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the Re-Ly trial. Stroke 43(6):1511–1517CrossRefPubMed
69.
Purrucker JC, Haas K, Rizos T, Khan S, Wolf M, Hennerici MG, Poli S, Kleinschnitz C, Steiner T, Heuschmann PU, Veltkamp R (2016) Early clinical and radiological course, management, and outcome of cerebral hemorrhage related to new oral anticoagulants. JAMA Neurol 73(2):169–177CrossRefPubMed
70.
Flibotte JJ, Hagan N, O’Donell J, Greenberg SM, Rosand J (2004) Warfarin, hemotoma expansion, and outcome of intracerebral hemorrhage. Neurology 63:1059–1064CrossRefPubMed
71.
72.
Kuramatsu JB, Gerner ST, Schellinger PD, Glahn J, Endres M et al (2015) Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 313(8):824–836CrossRefPubMed
73.
Koscielny J, Rutkauskaite E (2015) Bleedings under NOAC (non Vitamin-K dependent oral anticoagulants). Evidence and practical management. Hamostaseologie 35(Suppl 1):S43–S53PubMed
74.
Sie P, Samama CM, Godier A, Rosenacher N, Steib A, Llau JV et al (2011) Sugery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Heamostasis. Arch Cardiovasc Dis 104:669–676CrossRefPubMed
75.
Lai A, Davidson N, Galloway SW, Thachil J (2014) Perioperative management of patients on new oral anticoagulants. Br J Surg 101:742–749CrossRefPubMed
76.
Perzborn E, Heitmeier S, Laux V, Buchmueller A (2014) Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VIIa in vitro. Thromb Res 133(4):671–681CrossRefPubMed
77.
Zhou W, Schwarting S, Illanes S, Liesz A, Midelhoff M, Zorn M, Bendszus M, Heiland S, van Ryn J, Veltkamp R (2011) Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 42(12):3594–3599CrossRefPubMed
Metadaten
Titel
Nicht-Vitamin-K-abhängige orale Antikoagulanzien
Notfallmanagement bei Patienten mit Blutungen unter oraler Antikoagulation
verfasst von
Priv.-Doz. Dr. med. J. Koscielny
Dr. C. Rosenthal
Prof. Dr. C. von Heymann
Publikationsdatum
12.04.2017
Verlag
Springer Medizin
Erschienen in
Notfall + Rettungsmedizin / Ausgabe 3/2017
Print ISSN: 1434-6222
Elektronische ISSN: 1436-0578
DOI
https://doi.org/10.1007/s10049-017-0289-3

Weitere Artikel der Ausgabe 3/2017

Qualitätsindikatoren und strukturelle Voraussetzungen für Cardiac-Arrest-Zentren – Deutscher Rat für Wiederbelebung/German Resuscitation Council (GRC)

  • Open Access
  • Konzepte – Stellungnahmen – Leitlinien

BV-ÄLRD wählte Notfall + Rettungsmedizin zu seiner Organzeitschrift

  • Editorial

Mitteilungen des DBRD

  • Mitteilungen des DBRD

Rechtliche Rahmenbedingungen in der präklinischen Notfallversorgung

  • Konzepte – Stellungnahmen – Leitlinien

Infektiologie und Hygiene bei Notfallpatienten

  • Einführung zum Thema

Mitteilungen des BV ÄLRD

  • Mitteilungen des BV ÄLRD